persist for weeks and lead to poor feeding and weight gain, as well as abnormal lung function. 21 Antenatal screening practices for CT vary around the world. We conducted a two-part survey from June 2015 to February 2016 to determine current national screening recommendations. We analyzed English language information on Ministry of Health websites regarding CT antenatal screening. We contacted the Ministry of Health directly (for whom English was the preferred language) if the information on the national antenatal screening was outdated or unavailable. In parallel, we sent a survey to the regional representative for maternal-child health from the World Health Organization (WHO) to help collect countrylevel data. Finally, we referenced primary country or regional policy documents. We found that only 13 countries have national policies for CT screening in pregnancy (Figure 1 ), including the following five European countries: Latvia, Estonia, Sweden, Bulgaria, and Germany. Due to the lack of policies for CT screening in pregnancy, adverse pregnancy outcomes and chlamydial conjunctivitis and pneumonia continue to be prevalent worldwide. For example, a 2008 study in the Netherlands found that between 61% and 64% of cases of neonatal conjunctivitis were from CT-infected mothers, while another study estimated that CT was the second most common respiratory pathogen identified in infants under six months. 16, 17 The risk of acquiring a CT infection during pregnancy can be high if sexual activity during pregnancy occurs, and if the male partner is not also screened and treated for CT infection. In addition, studies have demonstrated that antenatal CT screening of women was cost-effective, even at a low estimated prevalence of 3%. 22, 23 Considering the above-mentioned research, we strongly advise that the authors re-consider the evidence behind the adverse effects of CT during pregnancy, and the risk of chlamydial conjunctivitis and pneumonia in newborns. We suggest the authors recommend routine CT screening in all pregnant women, regardless of their age or risk factors, in the 2015 European Guidelines.
